Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

Bayer

Status: Enrolling

Conditions: Neovascular Glaucoma

Treatments: Drug: Aflibercept (Eylea, BAY86-5321)

Study type: Observational

Funder types: Industry

Identifiers

NCT04519619

21220

Details and patient eligibility

About

This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment.

The objective of this study is to assess safety and effectiveness of Eylea using in real clinical practice. Patients will be followed for a time period of 6 months from start of Eylea treatment or until it is no longer possible (e.g. lost to follow-up). In total, 480 patients will be recruited. For each patient, data are collected as defined in the electronic case report form (eCRF) at the initial visit, follow-up visit and final visit, either by routine clinical visits (as per investigators routine practice).

Enrollment: 480 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of NVG
• Patients who have received IVT-AFL treatment according to Japanese labeling.

Exclusion criteria

• Patients who are contraindicated based on approved label
• Diagnosis of other indication

Trial design

480 participants in 1 patient group

Aflibercept (Eylea, BAY86-5321)

Description:

Decision of Eylea treatment is made by attending investigators according to the Japanese Package Insert

Treatment:

Drug: Aflibercept (Eylea, BAY86-5321)